Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis

doi:10.12114/j.issn.1007-9572.2024.0274

Chinese General Practice ›› 2026, Vol. 29 ›› Issue (12): 1588-1598.DOI: 10.12114/j.issn.1007-9572.2024.0274

• Article • Previous Articles Next Articles

Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis

1. Guangdong Research Institute for Orthopedics & Traumatology of TCM, Guangzhou 510378, China
2. Department of Joint Diseases, Joint Center of the Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510378, China
3. The Fifth Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China
4. State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou 510000, China

Received:2024-08-10 Revised:2024-12-15 Published:2026-04-20 Online:2026-03-12
Contact: WEI Qiushi

绝经后膝骨关节炎患者"中医证型-临床特征-分子分型"多维关系研究

1．510378　广东省广州市，广东省中医骨伤研究院
2．510378　广东省广州市，广州中医药大学第三附属医院关节中心关节科
3．510000　广东省广州市，广州中医药大学第五临床医学院
4．510000　广东省广州市，中医证候全国重点实验室

通讯作者: 魏秋实
作者简介:
作者贡献：
何晓铭负责文章撰写；何敏聪、魏腾飞、林天烨负责统计学处理及图表的绘制与展示；何晓铭负责数据的收集与整理；刘文刚、张庆文、何伟、魏秋实提出主要研究目标，负责研究方案的构思、设计与论文修订；魏秋实负责文章的质量控制与审查。
基金资助:
国家自然科学基金面上项目(82274544); 国家自然科学基金青年基金项目(82004392); 广东省自然科学基金面上项目(2023A1515010551); 广东省中医药重点学科建设项目(20220101); 2022年毕节市科学技术局2022年度"揭榜挂帅"项目(毕科合重大专项〔2022〕1号); 广东省教育厅普通高校重点领域专项(2021ZDZX2005); 广州市科学技术局2022年重点研发计划农业和社会发展科技项目专题(202206010184); 广东省中医药局科研项目(科研平台专项20254077); 广东省中医骨伤研究院开放基金课题重点项目(GYH202101-01，GYH202101-04); 广东省中医骨伤研究院开放基金课题一般项目(GYH202102-06); 广东省中医骨伤研究院开放基金课题青年基金项目(GYH202201-03); 广州中医药大学第三附属医院科研创新基金课题(Sy2022003)

Abstract

Abstract:

Background

Osteoporosis (OP) is a common clinical phenomenon in patients with knee osteoarthritis (KOA), but there lacks an unified homotherapy for heteropathy of OP and KOA.

Objective

To explore the multi-dimensional relationship of "traditional Chinese medicine (TCM) syndrome type- clinical feature-molecular typing" in patients with postmenopausal KOA, thus providing references for homotherapy for heteropathy of OP and KOA.

Methods

A total of 300 patients with postmenopausal KOA and treated with knee replacement surgery at the Joint Center of the Third Affiliated Hospital of Guangzhou University of Chinese Medicine from 2021 to 2023 were retrospectively included. According to the results of bone density measurement (BMD), patients were divided into three groups: normal bone density group, osteopenia group, and osteoporosis group, with 100 patients in each group. The correlation between the TCM syndrome type and BMD was analyzed in postmenopausal KOA patients by a correspondence analysis. The clinical symptoms [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score], laboratory indicators [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum calcium, phosphorus, alkaline phosphatase (ALP), and lipids)], and imaging indicators [Kellgren-Lawrence (K-L) grade, hip knee ankle angle (HKA), joint line convergence angle (JLCA), tibial plateau subchondral area, and low-density area] were investigated and compared among postmenopausal KOA patients with different TCM syndrome types. The knee joint tissues of KOA patients with different TCM syndrome types were analyzed by molecular biology, and the key target molecules were clarified. Subsequently, the key targets obtained by bioinformatics were detected by Western Blotting and immunohistochemistry experiments, and their expression differences were compared. An initial molecular classification of TCM syndrome types was established in patients with postmenopausal KOA.

Results

The main TCM syndrome types in postmenopausal women with KOA included the liver and kidney deficiency (n=122), Qi stagnation and blood stasis (n=96), cold and damp obstruction (n=72), and phlegm and blood stasis (n=10). Qi stagnation and blood stasis was the major TCM syndrome type in postmenopausal KOA patients with a normal BMD, while the liver and kidney deficiency dominant in those with decreased bone density and osteoporosis. There was a significant difference in the distribution of TCM syndrome times among the three groups (χ2=55.27, P<0.001). Logistic regression analysis showed that patients with the TCM syndrome of liver and kidney deficiency had a significantly higher risk of decreased bone density (OR=2.37, 95%CI=1.20-4.69, P=0.013) and osteoporosis (OR=3.39, 95%CI=2.41-4.76, P<0.001). Patients with the TCM syndrome of liver and kidney deficiency had significantly higher WOMAC body function scores and total WOMAC scores than those with Qi stagnation and blood stasis (P<0.05). There were no significant differences in ESR, CRP, total calcium, phosphorus, ALP, and four blood lipids between patients with the TCM syndrome types of liver and kidney deficiency, and Qi stagnation and blood stasis (P>0.05). The HKA was significantly smaller in patients with the TCM syndrome of liver and kidney deficiency than those with Qi stagnation and blood stasis, and the JLCA and tibial plateau subcutaneous low-density area were significantly larger (P<0.05). There was no significant difference in the area of the tibial plateau between the two TCM types of patients (P> 0.05). There was a significant difference in K-L grade between the TCM syndrome types of liver and kidney deficiency and Qi stagnation and blood stasis (P<0.05), with the former being R- significantly greater than the latter (P<0.05). Western Blotting and immunohistochemistry experiments showed that the expression levels of C-X-C chemokine ligand 8, tumor necrosis factor-alpha and interleukin-1beta molecules were significantly higher in patients with the TCM syndrome type of Qi stagnation and blood stasis, while the expression levels of peroxisome proliferator-activated receptor gamma, stearoyl-CoA desaturase and CCAAT/enhancer-binding protein alpha molecules were significantly higher in patients with the TCM syndrome type of liver and kidney deficiency (P<0.05).

Conclusion

The multidimensional relationships between "TCM syndrome type-clinical features-molecular typing" in postmenopausal KOA patients are as follows: patients with Qi stagnation and blood stasis have normal bone mass and increased expressions of inflammation-related molecules, and those with liver and kidney deficiency have decreased/osteoporotic bone mass and increased expressions of lipid metabolism-related molecules. Compared with Qi stagnation and blood stasis, patients with liver and kidney deficiency have a higher risk of decreased bone mass, osteoporosis, and lower limb inversion deformity. Their tibial plateau subchondral low-density area is significantly larger, knee function is significantly impaired, and the K-L grade is more severe.

Key words: Osteoarthritis, knee, Osteoporosis, postmenopausal, TCM syndrome type, Clinical features, Molecular typing, Same treatment for different diseases

摘要：

背景

膝骨关节炎（KOA）患者合并骨质疏松症临床常见，但二者的异病同治目前尚无统一方案。

目的

探讨绝经后KOA患者"中医证型-临床特征-分子分型"的多维关系，为KOA和骨质疏松的异病同治提供研究基础。

方法

回顾性选取2021—2023年于广州中医药大学第三附属医院关节中心住院确诊为绝经后KOA且接受膝关节置换术的患者300例作为研究对象，按照骨密度检查结果分为骨量正常组、骨量减少组和骨质疏松组，每组各100例。采用对应分析法探讨绝经后KOA患者中医证型与骨密度的相关性。调查不同中医证型绝经后KOA患者的临床症状[西安大略和麦克马斯特大学骨关节指数（WOMAC）]、实验室检查指标（C反应蛋白、红细胞沉降率、血钙、血磷、碱性磷酸酶、血脂）和影像学指标[影像学Kellgren-Lawrenc（K-L）分级、髋膝踝角（HKA）、关节线夹角（JLCA）、胫骨平台下面积及低密度影面积]，并进行比较。对不同中医证型KOA患者膝关节标本进行分子生物学分析，明确关键标靶分子，随后通过Western Blotting法和免疫组化实验检测生物信息学分析获得的关键靶标，比较不同中医症候绝经后KOA患者的分子表达差异，初步建立不同中医证候的分子分型。

结果

300例绝经后KOA患者的主要中医证候可归纳为肝肾亏虚证、气滞血瘀证、寒湿痹阻证和痰瘀互结证，分别为122、96、72、10例，其中骨量正常组中医证候主要表现为气滞血瘀证，而骨量减少、骨质疏松组中医证候则主要表现为肝肾亏虚证。３组不同骨密度类型患者的中医证候比较，差异有统计学意义（χ²=55.27，P<0.001）。Logistic回归分析显示，肝肾亏虚证患者出现骨量减少（OR=2.37，95%CI=1.20~4.69，P=0.013）、骨质疏松（OR=3.39，95%CI=2.41~4.76，P<0.001）的风险更高。肝肾亏虚证患者WOMAC身体功能评分与WOMAC总分高于气滞血瘀证患者（P<0.05），肝肾亏虚证和气滞血瘀证患者红细胞沉降率、C反应蛋白、血钙、血磷和碱性磷酸酶及血脂四项比较，差异均无统计学意义（P>0.05）。肝肾亏虚证患者的HKA小于气滞血瘀证患者，JLCA、胫骨平台下低密度影面积大于气滞血瘀证患者（P<0.05），两个证型患者的胫骨平台下面积比较，差异无统计学意义（P>0.05）。肝肾亏虚证和气滞血瘀证患者K-L分级比较，差异有统计学意义（P<0.05），肝肾亏虚证平均秩次（R-）大于气滞血瘀证患者（P<0.05）。Western Blotting和免疫组化试验表明，气滞血瘀证患者的趋化因子蛋白8、肿瘤坏死因子α、白介素1β分子表达量升高，而肝肾亏虚证氧化物酶体增殖物激活受体γ、硬脂酰-辅酶A去饱和酶和CCAAT增强子结合蛋白α分子表达量升高（P<0.05）。

结论

绝经后KOA患者"中医证型-临床特征-分子分型"的多维关系为："气滞血瘀-骨量正常-炎症相关分子表达升高"和"肝肾亏虚-骨量减少/骨质疏松-脂代谢相关分子表达升高"。相较气滞血瘀证而言，肝肾亏虚证患者发生骨量减少、骨质疏松的风险更高，更易发生下肢内翻畸形，其胫骨平台下低密度影面积明显更大，膝关节功能显著降低，K-L分级更为严重。

关键词: 骨关节炎，膝, 骨质疏松，绝经后, 中医证型, 临床特征, 分子分型, 异病同治

CLC Number:

R 684.3

HE Xiaoming,HE Mincong,WEI Tengfei, et al. Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis[J]. Chinese General Practice, 2026, 29(12): 1588-1598. DOI: 10.12114/j.issn.1007-9572.2024.0274.
何晓铭,何敏聪,魏腾飞等. 绝经后膝骨关节炎患者"中医证型-临床特征-分子分型"多维关系研究[J]. 中国全科医学, 2026, 29(12): 1588-1598. DOI: 10.12114/j.issn.1007-9572.2024.0274.

Figures/Tables 16

References 24

[1]	JANG S, LEE K, JU J H. Recent updates of diagnosis, pathophysiology, and treatment on osteoarthritis of the knee[J]. Int J Mol Sci, 2021, 22(5): 2619. DOI: 10.3390/ijms22052619.
[2]	WHITTAKER J L, TRUONG L K, DHIMAN K, et al. Osteoarthritis year in review 2020: rehabilitation and outcomes[J]. Osteoarthritis Cartilage, 2021, 29(2): 190-207. DOI: 10.1016/j.joca.2020.10.005.
[3]	王绍龙, 李腾飞, 郭宗磊, 等. 绝经后膝骨关节炎患者骨密度与内翻畸形的相关性研究[J]. 医学研究杂志, 2023, 52(1): 84-88, 92. DOI: 10.11969/j.issn.1673-548X.2023.01.020.
[4]	叶恒力, 高欢欢, 傅繁誉, 等. 基于现代文献的膝骨关节炎中医证型与证素分布规律研究[J]. 海南医学院学报, 2020, 26(1): 47-52. DOI: 10.13210/j.cnki.jhmu.20191224.003.
[5]	ZHANG C, ZHUANG Z K, CHEN X J, et al. Osteoporosis is associated with Varus deformity in postmenopausal women with knee osteoarthritis: a cross-sectional study[J]. BMC Musculoskelet Disord, 2021, 22(1): 694. DOI: 10.1186/s12891-021-04580-3.
[6]	齐晓凤, 王腾腾, 梁倩倩, 等. 膝骨关节炎中医证型的研究现状[J]. 世界科学技术-中医药现代化, 2016, 18(11): 1879-1882. DOI: 10.11842/wst.2016.11.008.
[7]	中国中西医结合学会骨伤科专业委员会. 膝骨关节炎中西医结合诊疗指南[J]. 中华医学杂志, 2018, 98(45): 3653-3658. DOI: 10.3760/cma.j.issn.0376-2491.2018.45.005.
[8]	许学猛, 刘文刚, 许树柴, 等. 膝骨关节炎(膝痹)中西医结合临床实践指南[J]. 实用医学杂志, 2021, 37(22): 2827-2833. DOI: 10.3969/j.issn.1006?5725.2021.22.001.
[9]	陈卫衡. 膝骨关节炎中医诊疗指南(2020年版)[J]. 中医正骨, 2020, 32(10): 1-14.
[10]	KELLGREN J H, LAWRENCE J S. Radiological assessment of osteo-arthrosis[J]. Ann Rheum Dis, 1957, 16(4): 494-502. DOI: 10.1136/ard.16.4.494.
[11]	詹芝玮, 韦雨柔, 林天烨, 等. 膝骨关节炎内翻畸形与胫骨平台下低密度影面积的关联[J]. 中华关节外科杂志:电子版, 2023, 17(2): 209-215. DOI: 10.3877/cma.j.issn.1674-134X.2023.02.009.
[12]	韩龙飞, 林天烨, 何敏聪, 等. 胫骨平台下低密度区骨量及体积对下肢力线影响的有限元分析[J]. 中国修复重建外科杂志, 2024, 38(6): 734-741. DOI: 10.7507/1002-1892.202312026.
[13]	BOER C G, HATZIKOTOULAS K, SOUTHAM L, et al. Deciphering osteoarthritis genetics across 826, 690 individuals from 9 populations[J]. Cell, 2021, 184(24): 6003-6005. DOI: 10.1016/j.cell.2021.11.003.
[14]	D'SOUZA N, CHARLTON J, GRAYSON J, et al. Are biomechanics during gait associated with the structural disease onset and progression of lower limb osteoarthritis? A systematic review and meta-analysis[J]. Osteoarthritis Cartilage, 2022, 30(3): 381-394. DOI: 10.1016/j.joca.2021.10.010.
[15]	陈能, 陈国材, 刘文刚, 等. 膝骨关节炎内翻畸形影响因素及治疗的研究进展[J]. 风湿病与关节炎, 2017, 6(5): 73-76, 80. DOI: 10.3969/j.issn.2095-4174.2017.05.020.
[16]	GARCIA S A, VAKULA M N, HOLMES S C, et al. The influence of body mass index and sex on frontal and sagittal plane knee mechanics during walking in young adults[J]. Gait Posture, 2021, 83: 217-222. DOI: 10.1016/j.gaitpost.2020.10.010.
[17]	TATEUCHI H. Gait- and postural-alignment-related prognostic factors for hip and knee osteoarthritis: toward the prevention of osteoarthritis progression[J]. Phys Ther Res, 2019, 22(1): 31-37. DOI: 10.1298/ptr.R0003.
[18]	许丽梅, 董丹宇, 薛维婳, 等. 从铁死亡探讨独活寄生汤防治骨关节炎的机制[J]. 中医学报, 2023, 38(12): 2554-2559. DOI: 10.16368/j.issn.1674-8999.2023.12.409.
[19]	曾嘉旭, 何琪, 陈柏豪, 等. 以"血瘀"理论指导治疗:解读膝骨关节炎"铁超载"的相关机制[J]. 中国组织工程研究, 2024, 28(11): 1743-1748. DOI: 10.12307/2024.237.
[20]	叶厚龙. 血友病性关节炎软骨下骨中铁超载的现象及铁死亡相关蛋白的表达[D]. 合肥: 安徽医科大学, 2023. DOI: 10.26921/d.cnki.ganyu.2023.000731.
[21]	HOSSEINZADEH A, KAMRAVA S K, JOGHATAEI M T, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin[J]. J Pineal Res, 2016, 61(4): 411-425. DOI: 10.1111/jpi.12362.
[22]	WANG S, ZHANG Z W, LIANG J H, et al. Identification of several inflammation-related genes based on bioinformatics and experiments[J]. Int Immunopharmacol, 2023, 121: 110409. DOI: 10.1016/j.intimp.2023.110409.
[23]	MALFAIT A M, SCHNITZER T J. Towards a mechanism-based approach to pain management in osteoarthritis[J]. Nat Rev Rheumatol, 2013, 9(11): 654-664. DOI: 10.1038/nrrheum.2013.138.
[24]	SONG J, CHANG A H, CHANG R W, et al. Relationship of knee pain to time in moderate and light physical activities: data from osteoarthritis initiative[J]. Semin Arthritis Rheum, 2018, 47(5): 683-688. DOI: 10.1016/j.semarthrit.2017.10.005.

骨密度类型	例数	气滞血瘀	寒湿痹阻	肝肾亏虚	痰瘀互结
骨量正常	100	49（49.00）	15（15.00）	32（32.00）	4（4.00）
骨量减少	100	20（20.00）	45（45.00）	31（31.00）	4（4.00）
骨质疏松	100	27（27.00）	12（12.00）	59（59.00）	2（2.00）

骨密度类型	例数	气滞血瘀	寒湿痹阻	肝肾亏虚	痰瘀互结
骨量正常	100	49（49.00）	15（15.00）	32（32.00）	4（4.00）
骨量减少	100	20（20.00）	45（45.00）	31（31.00）	4（4.00）
骨质疏松	100	27（27.00）	12（12.00）	59（59.00）	2（2.00）

自变量	因变量	B	OR值	95%CI	P值
气滞血瘀证	骨量减少	0.51	1.67	0.83~3.32	0.137
	骨质疏松	0.19	1.21	0.39~2.99	0.786
寒湿痹阻证	骨量减少	-0.25	0.72	0.38~1.45	0.337
	骨质疏松	0.04	1.15	0.67~1.98	0.576
肝肾亏虚证	骨量减少	0.87	2.37	1.20~4.69	0.013
	骨质疏松	1.25	3.39	2.41~4.76	<0.001
痰瘀互结证	骨量减少	-0.22	0.61	0.29~1.30	0.177
	骨质疏松	0.02	1.04	0.56~1.79	0.561

自变量	因变量	B	OR值	95%CI	P值
气滞血瘀证	骨量减少	0.51	1.67	0.83~3.32	0.137
	骨质疏松	0.19	1.21	0.39~2.99	0.786
寒湿痹阻证	骨量减少	-0.25	0.72	0.38~1.45	0.337
	骨质疏松	0.04	1.15	0.67~1.98	0.576
肝肾亏虚证	骨量减少	0.87	2.37	1.20~4.69	0.013
	骨质疏松	1.25	3.39	2.41~4.76	<0.001
痰瘀互结证	骨量减少	-0.22	0.61	0.29~1.30	0.177
	骨质疏松	0.02	1.04	0.56~1.79	0.561

证型	例数	年龄（±s，岁）	疼痛时间[M（P₂₅，P₇₅），年]
肝肾亏虚证	122	65.8±8.5	5.00（2.00，10.00）
气滞血瘀证	96	65.6±8.4	4.00（1.00，9.25）
t（Z）值		0.120	-0.983^a
P值		0.905	0.325

Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis

绝经后膝骨关节炎患者"中医证型-临床特征-分子分型"多维关系研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 16

References 24

Related Articles 10

Recommended Articles

Metrics

Comments

证型	例数	疼痛	僵硬	身体功能	WOMAC总分
肝肾亏虚证	122	12.00（11.00，13.00）	4.00（3.00，4.00）	36.50（31.75，43.00）	53.00（46.00，59.00）
气滞血瘀证	96	11.00（10.00，13.00）	4.00（3.00，4.00）	34.00（27.75，39.25）	49.00（43.00，54.00）
Z值		-1.887	-0.705	-2.848	-3.262
P值		0.059	0.481	0.004	0.001

证型	例数	ESR（mm/1 h）	CRP（mg/L）	血钙（mmol/L）	血磷（mmol/L）	碱性磷酸酶（U/L）
肝肾亏虚证	122	19.55（13.73，27.15）	5.68（1.99，8.04）	2.30（2.23，2.37）	1.19（1.09，1.28）	83.15（71.10，100.53）
气滞血瘀证	96	20.60（14.60，35.40）	5.72（1.37，9.24）	2.30（2.23，2.36）	1.16（1.05，1.26）	83.30（71.50，100.05）
Z值		-1.531	-0.010	-0.253	-1.275	-0.013
P值		0.126	0.992	0.800	0.202	0.990

证型	例数	三酰甘油	总胆固醇	高密度脂蛋白	低密度脂蛋白
肝肾亏虚证	122	1.81（1.24，2.65）	5.28（4.64，5.90）	1.30（1.11，1.49）	3.11（2.58，3.88）
气滞血瘀证	96	1.66（1.21，2.35）	5.44（4.87，6.06）	1.31（1.15，1.61）	3.28（2.79，3.85）
Z值		-0.941	-0.889	-1.079	-0.906
P值		0.347	0.374	0.280	0.365

证型	例数	HKA	JLCA	胫骨平台下面积（mm²）	胫骨平台下低密度影面积（mm²）
肝肾亏虚证	122	174.0°（170.0°，178.0°）	4.0°（2.8°，6.0°）	2 165.7（2 017.1，2 358.7）	1 107.41（962.3，1 291.7）
气滞血瘀证	96	177.0°（174.0°，179.0°）	3.0°（2.0°，4.0°）	2 131.5（1 908.8，2 365.9）	1 013.45（838.7，1 133.1）
Z值		-4.367	-4.991	-0.883	-3.067
P值		<0.001	<0.001	0.377	0.002

证型	例数	Ⅱ级	Ⅲ级	Ⅳ级
肝肾亏虚证	122	6（4.9）	43（35.2）	73（59.8）	118.34
气滞血瘀证	96	10（10.4）	36（37.5）	50（52.0）	102.66

证型	例数	IL-6	MMP9	TNF-α	CXCL8	IL-1β
肝肾亏虚证	3	0.09±0.01	0.37±0.09	0.16±0.05	0.10±0.02	0.05±0.01
气滞血瘀证	3	0.67±0.12	0.44±0.10	0.30±0.04	0.23±0.03	0.20±0.05
t值		8.343	0.901	3.787	6.245	5.205
P值		0.001	0.418	0.019	0.003	0.006

证型	例数	PPAR-γ	SCD	FABP4	C/EBPα	TGF-β
肝肾亏虚证	3	1.06±0.18	0.38±0.09	0.23±0.07	0.59±0.11	0.05±0.01
气滞血瘀证	3	0.61±0.09	0.18±0.04	0.20±0.05	0.17±0.03	0.20±0.05
t值		3.873	3.517	0.604	6.380	1.480
P值		0.017	0.024	0.578	0.003	0.213

证型	例数	IL-6	MMP9	TNF-α	CXCL8	IL-1β
肝肾亏虚证	3	6.81±1.91	9.11±3.21	16.54±4.67	4.79±2.31	12.36±2.66
气滞血瘀证	3	7.18±2.10	13.95±2.98	29.75±5.78	13.86±1.54	19.93±3.39
t值		0.225	1.914	3.079	5.659	3.043
P值		0.832	0.128	0.037	0.004	0.038

证型	例数	PPAR-γ	SCD	FABP4	C/EBPα	TGF-β
肝肾亏虚证	3	33.56±9.34	29.38±5.67	14.33±4.99	34.89±8.67	18.45±9.87
气滞血瘀证	3	10.12±2.11	9.73±1.45	14.56±4.89	12.44±1.66	17.89±6.58
t值		4.240	5.815	0.057	4.405	0.081
P值		0.013	0.004	0.957	0.011	0.938

[1]	XIA Ning, SHI Lan, DING Wanbao, ZHANG Jie, LONG Yi, DAI Hui, ZHANG Can, DAI Hailong. Clinical Characteristics and Prognosis of Patients with Amyloidosis [J]. Chinese General Practice, 2026, 29(09): 1161-1167.
[2]	WU Yu, SHANG Weijing, LIU Min, LIANG Wannian. Early Identification of Mpox Clinical Features and Its Significance for Epidemic Control [J]. Chinese General Practice, 2025, 28(04): 465-469.
[3]	XUE Jingru, SUN Suzhen. Clinical Characteristics and Risk Factors for Unfavourble Prognosis of Mycoplasma Pneumoniae Encephalitis in Children [J]. Chinese General Practice, 2023, 26(17): 2125-2131.
[4]	GENG Tonghui, LI Han, JIN Jingjing, CHENG Meijuan, ZHANG Shenglei, BAI Yaling, XU Jinsheng. Clinicopathological Features of Anticancer Drug-induced Kidney Injury [J]. Chinese General Practice, 2022, 25(33): 4153-4158.
[5]	DING Hang, LIU Yuan, ZHANG Lianfeng, ZHOU Lin. Clinical Featuresof IgG4-related Disease [J]. Chinese General Practice, 2022, 25(05): 584-588.
[6]	ZHANG Maowei，CHEN Bi，ZHU Jiechen，LIU Yanan，ZHAO Ling，JI Lei，LIU Wenjing，ZHU Shuyang，ZHANG Wenhui. Clinical Characteristics of Obstructive Sleep Apnea-hypopnea Syndrome Patients with Different Degrees of Obesity [J]. Chinese General Practice, 2020, 23(22): 2809-2814.
[7]	SU Baolin，LI Jing，TANG Shuifu，CHEN Gangyi. TCM Syndrome Types of Diabetic Nephropathy and Their Correlation with Laboratory Indices 　 [J]. Chinese General Practice, 2020, 23(1): 70-74.
[8]	WANG Xiaohong，ZHU Shuangshuang，LIU Aiqun，LIU Qin，LI Yongqiang，XIONG Zhongxiang，GUO Ze，ZOU Hequn. Clinical Characteristics of Hypertriglyceridemic Waist Phenotype and Its Relationship with Pre-diabetes and Diabetes Mellitus　 [J]. Chinese General Practice, 2019, 22(19): 2340-2344.
[9]	MA Lilan，YANG Ying，CHEN Zhangrong，WU Xinhua，CHEN Anqi，LIU Hong，LIU Quanyi，YANG Wei，ZHANG Jian. Retrospective Study of the Incidence of Heart Failure in Southwest China　 [J]. Chinese General Practice, 2019, 22(14): 1678-1683.
[10]	SHI Yuheng，CHEN Yanyan，MA Jiayun. Diagnosis Delay and Clinical Characteristics of Patients with Acute Pulmonary Embolism in Outpatient Clinics [J]. Chinese General Practice, 2018, 21(31): 3832-3836.